B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof
A b7.1-cd19scfv, B lymphocyte technology, applied in the direction of genetic engineering, hybrid immunoglobulin, plant genetic improvement, etc. Promoting clonal proliferation, prolonging survival, significant immunotherapeutic effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0032] The B7.1-CD19scFv fusion genetically engineered protein for the treatment of B lymphocytic leukemia and lymphoma of the present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments:
[0033] 1. Cloning of Human Self-Cell Surface Antigen B7.1 Gene
[0034] 1. The human B7.1 differentiation antigen cDNA sequence was searched from the GenBank database of the US National Library of Medicine website (http: / / www.ncbi.nlm.nih.gov / entrez), and primers were designed with the help of primer design software primer 3.
[0035] Primers for amplifying the extracellular region of B7.1:
[0036] primer-sen: 5'-ccg gaattc ggtgttatccacgtgac-3'
[0037] EcoRI
[0038] Antisen: 5'-ccc aagctt tgtattccagttgaagg-3'
[0039] Hind III
[0040] 2. RT-PCR amplification of human B7.1 gene
[0041] 2.1 Extract total RNA from B lymphocytes expressing B7.1.
[0042] (1) Take about 10 ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com